Form Type:  8-K
Filing Date:  3/2/2023 
CIK:  0001175680 
Address:  1111 MAIN STREET, SUITE 660 
City, State, Zip:  VANCOUVER, Washington 98660 
Telephone:  360-980-8524 
Fiscal Year:  05/31 
Last Trade
Last Trade: 
-0.01 (-3.48%)  
Trade Time: 
Jun 07  
Market Cap: 
Trade CYDY now with 

© 2023  
Description of Business
CytoDyn Inc. (together with its wholly owned subsidiaries, the "Company", also referred to as "CytoDyn", "we," "our," or "us" in this Form 10-K) was originally incorporated under the laws of Colorado on May 2, 2002, under the name RexRay Corporation and, effective August 27, 2015, reincorporated under the laws of Delaware. The Company is a clinical-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab (also referred to as PRO 140 in this Form 10-K), a novel humanized monoclonal antibody targeting the CCR5 receptor. The pre-clinical and early clinical development of PRO 140 was led by Progenics Pharmaceuticals, Inc. ("Progenics") through 2011. The Company acquired the asset from Progenics in October 2012; refer to Part II, Item 8, Note 10, Commitments and Contingencies - PRO 140 Acquisition and Licensing Arrangements of this Form 10-K for additional information.
Register and access this filing in:     
  FORM 8-K
      Item 3.02 Unregistered Sales of Equity Securities.

EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.